These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29748210)

  • 21. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
    Kohlhagen G; Paull KD; Cushman M; Nagafuji P; Pommier Y
    Mol Pharmacol; 1998 Jul; 54(1):50-8. PubMed ID: 9658189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
    Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
    J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview on the development of new potentially active camptothecin analogs against cancer.
    Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
    Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.
    Watson VG; Hardison NE; Harris T; Motsinger-Reif A; McLeod HL
    Mol Cancer Ther; 2011 Oct; 10(10):1839-45. PubMed ID: 21750217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
    Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
    Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
    Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
    van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
    J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
    Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors.
    Sheng C; Miao Z; Zhang W
    Curr Med Chem; 2011; 18(28):4389-409. PubMed ID: 21861816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y; Takebayashi Y; Pommier Y
    Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
    Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
    Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
    Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
    Zhao H; Rybak P; Dobrucki J; Traganos F; Darzynkiewicz Z
    Cytometry A; 2012 Jan; 81(1):45-51. PubMed ID: 22140093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
    Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
    Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 40. Topoisomerase I inhibitors: Challenges, progress and the road ahead.
    Talukdar A; Kundu B; Sarkar D; Goon S; Mondal MA
    Eur J Med Chem; 2022 Jun; 236():114304. PubMed ID: 35413618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.